Group
Gamma-secretase inhibitor
Group Profile
| Therapeutic Class | Targeted Therapy |
| Drug Class | Other Targeted Agents |
| Mechanism of Action | Gamma-secretase inhibitor |
| Drugs in group | Nirogacestat |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
Radiosensitizing in Notch-active tumors (↑DNA damage, ↓DNA-PK, ↓stem survival) (Mizugaki et al., British Journal of Cancer, 2012; Zhang et al., European Journal of Pharmacology, 2018). Notch is critical to GI and skin epithelial homeostasis, so a theoretical increase in in-field GI/mucocutaneous adverse events is plausible (GI adverse events are a known class effect).
The data above refer to patients treated with Gamma-secretase inhibitor as the sole drug class,
excluding any concurrent use of drugs from other groups.
Individual Drugs
Select a drug to view its individual evidence base (drug + SBRT, no other concurrent systemic drugs). Drugs without available data are shown greyed out.